Sylvia Kerr, APRN-CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 927 Kenton Station Dr, Maysville, KY 41056 Phone: 606-759-5331 Fax: 606-759-5363 |
Rebecca S. Hogge, CNM, ARNP Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 927 Kenton Station Dr, Maysville, KY 41056 Phone: 606-759-5331 Fax: 606-759-5363 |
Heather Ann Wilson, ARNP, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 927 Kenton Station Dr, Maysville, KY 41056 Phone: 606-759-5331 Fax: 606-759-5363 |
News Archive
Synexus has created a specialist vaccines team to help pharma and biotech companies find the thousands of patients they need for their late phase trials. The company has a well-established reputation for delivering results in the vaccine field following successes in late phase vaccine trials including most recently, studies for cancer prevention, influenza and rotavirus where it has delivered in excess of three thousand randomised patients in all three areas.
Nicast, developer of medical devices made of electrospun nanofabric, announced today it is readying to launch the NovaMesh intra-abdominal hernia mesh in the European market in Q1 2010, pending European regulatory approval. NovaMesh is the first intra-abdominal hernia mesh to utilize the special properties of electrospun nanofabric.
Getinge announces the next edition of the Intensive Care Unit (ICU) Experience which will take place in the Getinge Experience Center, Rastatt on Tuesday 19 September 2017. Over 50 customers from across Europe, Middle East & Africa will be in attendance and have the opportunity to network with scientific experts and medical device industry.
Led by researchers at the University of Pittsburgh School of Medicine, an international panel of pathologists and clinicians has reclassified a type of thyroid cancer to reflect that it is noninvasive and has a low risk of recurrence. The name change, described today in JAMA Oncology, is expected to reduce the psychological and medical consequences of a cancer diagnosis, potentially affecting thousands of people worldwide.
Various active substances in oral antidiabetic agents are frequently combined in the treatment of diabetes in order to achieve an effective reduction in the blood sugar. A new, very promising approach combines the substances metformin and SGLT2 inhibitors, the latter were just approved in 2012.
› Verified 4 days ago